you are here: Home News Novartis

Novartis

India revokes patent of Novartis' cardiac drug Vymada: Report
First malaria drug for babies approved; set for rollout in Africa within weeks
Trump Tariff – How much can it hurt Indian pharma?
Divi's Labs shares fall nearly 3% as US court says Novartis cannot block generic of best-selling heart drug
Alkem Labs in talks to acquire Novartis AG's India unit: CNBC-TV18
Novartis raises guidance after beating Q1 expectations
Dr. Reddy's eyeing to acquire Novartis' India arm: Report
Novartis to acquire cancer-centric MorphoSys for $2.9 billion
World Street | China's market restrictions, Novartis' M&A bid, Yandex's Russia exit, Estee Lauder's jobs cuts and more
JB Pharma inks Rs 964-cr licence deal with Novartis for ophthalmology brands
We invest 20% of our revenue towards overall research including cancer: Novartis India MD
Fit to Lead | Novartis India’s Amitabh Dube: ‘Focus keeps you on the right track, discipline helps you to be consistent’
Novartis to buy Chinook for up to $3.5 billion in boost to late-stage pipeline
Global pharma companies pushing to innovate in India: OPPI president
Cipla inks licensing pact with Novartis for diabetes drug
Novartis launches new $11 billion share buyback
Novartis, Eli Lilly get court notices in case related to breast cancer drugs
Novartis CEO on how yoga & lessons from his grandparents help him take big professional decisions
How yoga since childhood days helped this Indian-origin CEO
‘Indian-origin CEOs take pride in identity’: Novartis’s Vas Narasimhan
Novartis global chief focuses on innovative medicines for Indian market
MC Analysis I Why India’s cardiology pharma market is expecting a major disruption this year
Glenmark generics for heart failure drug to lower cost by up to 126%
US Supreme Court rebuffs Novartis, allows generic versions of MS drug
Novartis to spin off generics business Sandoz next year

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Novartis

India revokes patent of Novartis' cardiac drug Vymada: Report

First malaria drug for babies approved; set for rollout in Africa within weeks

Trump Tariff – How much can it hurt Indian pharma?

Divi's Labs shares fall nearly 3% as US court says Novartis cannot block generic of best-selling heart drug

Alkem Labs in talks to acquire Novartis AG's India unit: CNBC-TV18

Novartis raises guidance after beating Q1 expectations

Dr. Reddy's eyeing to acquire Novartis' India arm: Report

Novartis to acquire cancer-centric MorphoSys for $2.9 billion

World Street | China's market restrictions, Novartis' M&A bid, Yandex's Russia exit, Estee Lauder's jobs cuts and more

JB Pharma inks Rs 964-cr licence deal with Novartis for ophthalmology brands

We invest 20% of our revenue towards overall research including cancer: Novartis India MD

Fit to Lead | Novartis India’s Amitabh Dube: ‘Focus keeps you on the right track, discipline helps you to be consistent’

Novartis to buy Chinook for up to $3.5 billion in boost to late-stage pipeline

Global pharma companies pushing to innovate in India: OPPI president

Cipla inks licensing pact with Novartis for diabetes drug

Novartis launches new $11 billion share buyback

Novartis, Eli Lilly get court notices in case related to breast cancer drugs

Novartis CEO on how yoga & lessons from his grandparents help him take big professional decisions

How yoga since childhood days helped this Indian-origin CEO

‘Indian-origin CEOs take pride in identity’: Novartis’s Vas Narasimhan

Novartis global chief focuses on innovative medicines for Indian market

MC Analysis I Why India’s cardiology pharma market is expecting a major disruption this year

Glenmark generics for heart failure drug to lower cost by up to 126%

US Supreme Court rebuffs Novartis, allows generic versions of MS drug

Novartis to spin off generics business Sandoz next year